


**GUIDELINES FOR THE USE OF FENTANYL/BUPRENORPHINE TRANSDERMAL ANALGESIC PATCHES IN THE DYING PHASE IN PATIENTS WITH ABNORMAL RENAL FUNCTION ie. WHERE eGFR <30**

This algorithm is intended for use in patients who enter the dying phase and have a transdermal patch in situ/require analgesia. If in doubt regarding pain management please contact specialist palliative care team for advice  
CGH 3447, GRH 5179, OOH via switchboard 03004222222.



**Approximate PRN doses for breakthrough pain with Alfentanil Syringe Driver**

<b>Alfentanil (mg) Over 24hrs</b>	1	2	3	4	5	6	8	10	12	14
<b>Oxycodone (mg) s/c hrly PRN</b>	2	4	6	8	10	12	16	20	24	28

**Approximate PRN doses for breakthrough pain with Transdermal Patches**

<b>Fentanyl Patch (mcg/hr) changed 72hrly</b>	-	-	12	25	37	50	75	100	125	150
<b>BuTrans Buprenorphine (mcg/hr) changed weekly</b>	5	10	20	-	-	-	-	-	-	-
<b>TransTec Buprenorphine (mcg/hr) changed twice weekly</b>	-	-	-	35	52.5	70	-	-	-	-
<b>Oxycodone (mg) s/c hrly PRN</b>	1	1	2	4	6	8	12	15	17.5	20

**To calculate new breakthrough dose when a patient is on a patch and Alfentanil syringe driver**

(Fentanyl 25mcg/hr patch = Oxynorm 4mg sc for breakthrough pain) + (Alfentanil 2mg/24hrs via syringe driver = Oxynorm 4mg sc for breakthrough pain)

New dose for breakthrough pain = 4mg + 4mg = Oxynorm 8mg sc